vs
Day One Biopharmaceuticals, Inc.（DAWN）与FIDELITY D & D BANCORP INC（FDBC）财务数据对比。点击上方公司名可切换其他公司
Day One Biopharmaceuticals, Inc.的季度营收约是FIDELITY D & D BANCORP INC的1.6倍（$39.8M vs $24.4M），FIDELITY D & D BANCORP INC净利率更高（32.5% vs -49.6%，领先82.1%），FIDELITY D & D BANCORP INC同比增速更快（15.0% vs -57.6%）
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
Fidelity D & D Bancorp Inc是一家总部位于美国的地区性银行控股公司，主要在宾夕法尼亚州东北部开展业务，为个人消费者、小微企业及当地社区客户提供存款账户、消费及商业贷款、抵押贷款、财富管理等综合零售及商业银行服务。
DAWN vs FDBC — 直观对比
营收规模更大
DAWN
是对方的1.6倍
$24.4M
营收增速更快
FDBC
高出72.5%
-57.6%
净利率更高
FDBC
高出82.1%
-49.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.8M | $24.4M |
| 净利润 | $-19.7M | $7.9M |
| 毛利率 | — | — |
| 营业利润率 | -60.9% | 37.7% |
| 净利率 | -49.6% | 32.5% |
| 营收同比 | -57.6% | 15.0% |
| 净利润同比 | -153.3% | 36.1% |
| 每股收益（稀释后） | $-0.19 | $1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DAWNFDBC
| Q4 25 | — | $24.4M | ||
| Q3 25 | $39.8M | $23.5M | ||
| Q2 25 | $33.9M | $23.3M | ||
| Q1 25 | $30.8M | $22.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | $93.8M | $20.4M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | $0 | $19.5M |
净利润DAWNFDBC
| Q4 25 | — | $7.9M | ||
| Q3 25 | $-19.7M | $7.3M | ||
| Q2 25 | $-30.3M | $6.9M | ||
| Q1 25 | $-36.0M | $6.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $37.0M | $5.0M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | $-62.4M | $5.1M |
营业利润率DAWNFDBC
| Q4 25 | — | 37.7% | ||
| Q3 25 | -60.9% | 36.5% | ||
| Q2 25 | -103.1% | 35.5% | ||
| Q1 25 | -133.5% | 32.2% | ||
| Q4 24 | — | 31.4% | ||
| Q3 24 | 31.6% | 28.2% | ||
| Q2 24 | — | 28.9% | ||
| Q1 24 | — | 29.5% |
净利率DAWNFDBC
| Q4 25 | — | 32.5% | ||
| Q3 25 | -49.6% | 31.2% | ||
| Q2 25 | -89.4% | 29.7% | ||
| Q1 25 | -117.0% | 27.2% | ||
| Q4 24 | — | 27.5% | ||
| Q3 24 | 39.5% | 24.3% | ||
| Q2 24 | — | 25.0% | ||
| Q1 24 | — | 25.9% |
每股收益（稀释后）DAWNFDBC
| Q4 25 | — | $1.29 | ||
| Q3 25 | $-0.19 | $1.27 | ||
| Q2 25 | $-0.29 | $1.27 | ||
| Q1 25 | $-0.35 | $1.03 | ||
| Q4 24 | — | $1.00 | ||
| Q3 24 | $0.38 | $0.86 | ||
| Q2 24 | — | $0.86 | ||
| Q1 24 | $-0.72 | $0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $451.6M | $148.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.9M | $238.9M |
| 总资产 | $513.8M | $2.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DAWNFDBC
| Q4 25 | — | $148.1M | ||
| Q3 25 | $451.6M | $142.2M | ||
| Q2 25 | $453.1M | $165.5M | ||
| Q1 25 | $473.0M | $211.2M | ||
| Q4 24 | — | $83.4M | ||
| Q3 24 | $558.4M | $120.2M | ||
| Q2 24 | — | $78.1M | ||
| Q1 24 | $317.9M | $72.7M |
股东权益DAWNFDBC
| Q4 25 | — | $238.9M | ||
| Q3 25 | $450.9M | $229.2M | ||
| Q2 25 | $460.8M | $217.9M | ||
| Q1 25 | $479.5M | $211.7M | ||
| Q4 24 | — | $204.0M | ||
| Q3 24 | $555.5M | $207.3M | ||
| Q2 24 | — | $195.7M | ||
| Q1 24 | $296.8M | $191.6M |
总资产DAWNFDBC
| Q4 25 | — | $2.7B | ||
| Q3 25 | $513.8M | $2.7B | ||
| Q2 25 | $519.0M | $2.7B | ||
| Q1 25 | $534.4M | $2.7B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | $600.8M | $2.6B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | $326.6M | $2.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | $42.4M |
| 自由现金流经营现金流 - 资本支出 | — | $24.8M |
| 自由现金流率自由现金流/营收 | — | 101.7% |
| 资本支出强度资本支出/营收 | 0.0% | 71.9% |
| 现金转化率经营现金流/净利润 | — | 5.34× |
| 过去12个月自由现金流最近4个季度 | — | $45.4M |
8季度趋势，按日历期对齐
经营现金流DAWNFDBC
| Q4 25 | — | $42.4M | ||
| Q3 25 | $-5.8M | $8.4M | ||
| Q2 25 | $-24.8M | $12.6M | ||
| Q1 25 | $-59.0M | $11.7M | ||
| Q4 24 | — | $29.6M | ||
| Q3 24 | $50.8M | $9.1M | ||
| Q2 24 | — | $8.7M | ||
| Q1 24 | $-49.7M | $5.3M |
自由现金流DAWNFDBC
| Q4 25 | — | $24.8M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $-24.8M | $6.9M | ||
| Q1 25 | $-59.3M | $11.5M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | $50.0M | $7.8M | ||
| Q2 24 | — | $7.2M | ||
| Q1 24 | — | $4.0M |
自由现金流率DAWNFDBC
| Q4 25 | — | 101.7% | ||
| Q3 25 | — | 9.3% | ||
| Q2 25 | -73.2% | 29.6% | ||
| Q1 25 | -192.8% | 52.3% | ||
| Q4 24 | — | 117.3% | ||
| Q3 24 | 53.4% | 38.1% | ||
| Q2 24 | — | 36.6% | ||
| Q1 24 | — | 20.7% |
资本支出强度DAWNFDBC
| Q4 25 | — | 71.9% | ||
| Q3 25 | 0.0% | 26.5% | ||
| Q2 25 | 0.0% | 24.4% | ||
| Q1 25 | 1.0% | 0.8% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | 0.8% | 6.3% | ||
| Q2 24 | — | 7.5% | ||
| Q1 24 | — | 6.7% |
现金转化率DAWNFDBC
| Q4 25 | — | 5.34× | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.82× | ||
| Q1 25 | — | 1.95× | ||
| Q4 24 | — | 5.07× | ||
| Q3 24 | 1.37× | 1.83× | ||
| Q2 24 | — | 1.76× | ||
| Q1 24 | — | 1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
FDBC
暂无分部数据
